.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
US Army
Citi
Baxter
Fuji
Cipla
Colorcon
Teva
Farmers Insurance
McKesson

Generated: July 24, 2017

DrugPatentWatch Database Preview

Zanamivir - Generic Drug Details

« Back to Dashboard

What are the generic sources for zanamivir and what is the scope of zanamivir patent protection?

Zanamivir
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for Generic Name: zanamivir

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list40
Clinical Trials: see list23
Patent Applications: see list4,738
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:zanamivir at DailyMed

Pharmacology for Ingredient: zanamivir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: zanamivir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999► Subscribe► Subscribe
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999► Subscribe► Subscribe
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999► Subscribe► Subscribe
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999► Subscribe► Subscribe
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Chinese Patent Office
Merck
Fish and Richardson
Moodys
Argus Health
Cantor Fitzgerald
US Department of Justice
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot